Cargando…
Role of oral Minocycline in acute encephalitis syndrome in India – a randomized controlled trial
BACKGROUND: Acute encephalitis syndrome (AES) is a public health problem in India. Neuroinfections are believed to be the most important etiology. Minocycline is a semisythetic tetracycline having excellent penetration into cerebrospinal fluid, established neuroprotective and antiviral properties be...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4743094/ https://www.ncbi.nlm.nih.gov/pubmed/26847071 http://dx.doi.org/10.1186/s12879-016-1385-6 |
_version_ | 1782414295589453824 |
---|---|
author | Kumar, Rashmi Basu, Anirban Sinha, Subrata Das, Manoj Tripathi, Piyush Jain, Amita Kumar, Chandrakanta Atam, Virendra Khan, Saima Singh, Amit Shanker |
author_facet | Kumar, Rashmi Basu, Anirban Sinha, Subrata Das, Manoj Tripathi, Piyush Jain, Amita Kumar, Chandrakanta Atam, Virendra Khan, Saima Singh, Amit Shanker |
author_sort | Kumar, Rashmi |
collection | PubMed |
description | BACKGROUND: Acute encephalitis syndrome (AES) is a public health problem in India. Neuroinfections are believed to be the most important etiology. Minocycline is a semisythetic tetracycline having excellent penetration into cerebrospinal fluid, established neuroprotective and antiviral properties besides action on nonviral causes of AES. It has been shown to be effective in animal model of Japanese encephalitis (JE). A randomized, controlled trial of nasogastric/oral minocycline in JE and AES at a single centre in Uttar Pradesh, northern India, was therefore conducted. METHODS: Patients beyond 3 years of age - but excluding women aged 16–44 years - hospitalized with AES of < =7 days duration were enrolled and block randomized to receive nasogastric/oral minocycline or placebo suspension and followed up. Patients, study personnel and those entering data were blinded as to drug or placebo received. Primary outcome was cumulative mortality at 3 months from hospitalization. Analysis was by intention to treat. RESULTS: 281 patients were enrolled, 140 received drug and 141 placebo. While there was no overall statistically significant difference in 3 month mortality between drug and placebo groups [RR = 0 · 83 (0 · 6-1 · 1)], there were encouraging trends in patients older than 12 years [RR = 0.70 (0.41-1.18)] and in Glasgow Outcome Score (GOS) at 3 months (χ(2) = 7 · 44, p = 0 · 059). These trends were further accentuated if patients dying within one day of reaching hospital were excluded [OR for 3 month mortality =0 · 70 (0 · 46-1 · 07), p = 0.090; 3 month GOS p = 0 · 028]. CONCLUSIONS: A trend towards better outcomes was observed with minocycline, especially in those patients who survived the initial day in hospital. These findings should form the basis for planning a larger study and possibly including minocycline in the initial management of AES as seen here. TRIAL REGISTRATION: The trial was registered with Clinical Trials Registry of India (CTRI) - CTRI/2010/091/006143 |
format | Online Article Text |
id | pubmed-4743094 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-47430942016-02-06 Role of oral Minocycline in acute encephalitis syndrome in India – a randomized controlled trial Kumar, Rashmi Basu, Anirban Sinha, Subrata Das, Manoj Tripathi, Piyush Jain, Amita Kumar, Chandrakanta Atam, Virendra Khan, Saima Singh, Amit Shanker BMC Infect Dis Research Article BACKGROUND: Acute encephalitis syndrome (AES) is a public health problem in India. Neuroinfections are believed to be the most important etiology. Minocycline is a semisythetic tetracycline having excellent penetration into cerebrospinal fluid, established neuroprotective and antiviral properties besides action on nonviral causes of AES. It has been shown to be effective in animal model of Japanese encephalitis (JE). A randomized, controlled trial of nasogastric/oral minocycline in JE and AES at a single centre in Uttar Pradesh, northern India, was therefore conducted. METHODS: Patients beyond 3 years of age - but excluding women aged 16–44 years - hospitalized with AES of < =7 days duration were enrolled and block randomized to receive nasogastric/oral minocycline or placebo suspension and followed up. Patients, study personnel and those entering data were blinded as to drug or placebo received. Primary outcome was cumulative mortality at 3 months from hospitalization. Analysis was by intention to treat. RESULTS: 281 patients were enrolled, 140 received drug and 141 placebo. While there was no overall statistically significant difference in 3 month mortality between drug and placebo groups [RR = 0 · 83 (0 · 6-1 · 1)], there were encouraging trends in patients older than 12 years [RR = 0.70 (0.41-1.18)] and in Glasgow Outcome Score (GOS) at 3 months (χ(2) = 7 · 44, p = 0 · 059). These trends were further accentuated if patients dying within one day of reaching hospital were excluded [OR for 3 month mortality =0 · 70 (0 · 46-1 · 07), p = 0.090; 3 month GOS p = 0 · 028]. CONCLUSIONS: A trend towards better outcomes was observed with minocycline, especially in those patients who survived the initial day in hospital. These findings should form the basis for planning a larger study and possibly including minocycline in the initial management of AES as seen here. TRIAL REGISTRATION: The trial was registered with Clinical Trials Registry of India (CTRI) - CTRI/2010/091/006143 BioMed Central 2016-02-04 /pmc/articles/PMC4743094/ /pubmed/26847071 http://dx.doi.org/10.1186/s12879-016-1385-6 Text en © Kumar et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Kumar, Rashmi Basu, Anirban Sinha, Subrata Das, Manoj Tripathi, Piyush Jain, Amita Kumar, Chandrakanta Atam, Virendra Khan, Saima Singh, Amit Shanker Role of oral Minocycline in acute encephalitis syndrome in India – a randomized controlled trial |
title | Role of oral Minocycline in acute encephalitis syndrome in India – a randomized controlled trial |
title_full | Role of oral Minocycline in acute encephalitis syndrome in India – a randomized controlled trial |
title_fullStr | Role of oral Minocycline in acute encephalitis syndrome in India – a randomized controlled trial |
title_full_unstemmed | Role of oral Minocycline in acute encephalitis syndrome in India – a randomized controlled trial |
title_short | Role of oral Minocycline in acute encephalitis syndrome in India – a randomized controlled trial |
title_sort | role of oral minocycline in acute encephalitis syndrome in india – a randomized controlled trial |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4743094/ https://www.ncbi.nlm.nih.gov/pubmed/26847071 http://dx.doi.org/10.1186/s12879-016-1385-6 |
work_keys_str_mv | AT kumarrashmi roleoforalminocyclineinacuteencephalitissyndromeinindiaarandomizedcontrolledtrial AT basuanirban roleoforalminocyclineinacuteencephalitissyndromeinindiaarandomizedcontrolledtrial AT sinhasubrata roleoforalminocyclineinacuteencephalitissyndromeinindiaarandomizedcontrolledtrial AT dasmanoj roleoforalminocyclineinacuteencephalitissyndromeinindiaarandomizedcontrolledtrial AT tripathipiyush roleoforalminocyclineinacuteencephalitissyndromeinindiaarandomizedcontrolledtrial AT jainamita roleoforalminocyclineinacuteencephalitissyndromeinindiaarandomizedcontrolledtrial AT kumarchandrakanta roleoforalminocyclineinacuteencephalitissyndromeinindiaarandomizedcontrolledtrial AT atamvirendra roleoforalminocyclineinacuteencephalitissyndromeinindiaarandomizedcontrolledtrial AT khansaima roleoforalminocyclineinacuteencephalitissyndromeinindiaarandomizedcontrolledtrial AT singhamitshanker roleoforalminocyclineinacuteencephalitissyndromeinindiaarandomizedcontrolledtrial |